Antimicrobial Efficacy of a Taurolidine‐Based Antimicrobial Compound on Contaminated Surfaces Simulated in a Standardized 4‐Field Test

TL;DR

This study shows taurolidine is highly effective at killing bacteria and fungi on surfaces during simulated implant procedures, offering a new way to prevent device-related infections.

Contribution

Taurolidine's enzyme-independent antimicrobial mechanism and efficacy in short-contact, organic-load conditions are newly demonstrated for intraoperative surface disinfection.

Findings

Taurolidine achieved >5 log10 reductions in Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans.

It showed >4 log10 reduction in Enterococcus hirae under simulated clinical conditions.

The antimicrobial activity involves reactive N-methylol groups disrupting microbial membranes.

Abstract

Implantable medical devices, including cardiac electronic implants, joint prostheses, and breast implants, are essential to modern healthcare but remain susceptible to infection from microbial contamination during placement. Staphylococcus spp. and Candida albicans are the predominant pathogens, often causing severe complications, increased mortality, and substantial healthcare costs. With antibiotic resistance on the rise, intraoperative surface disinfection has emerged as a critical yet underutilized preventive strategy. Taurolidine, a broad‐spectrum antimicrobial with a strong safety profile and no known resistance, can be applied directly to both tissues and device surfaces. To replicate intraoperative decontamination, taurolidine‐saturated swabs are tested under standardized mechanical wiping using the European Norm EN 16615 “4‐field test.” The model reproduced short contact times and organic load conditions reflective of clinical practice, enabling assessment of both chemical and mechanical antimicrobial effects. Taurolidine achieved >5 log10 reductions in Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans, and >4 log10 for Enterococcus hirae. The observed activity demonstrated a surface‐driven, enzyme‐independent mechanism involving spontaneous release of reactive N‐methylol functional groups that disrupt microbial membranes. Taurolidine's enzyme‐independent antimicrobial mechanism distinguishes it from solvent‐ or oxidant‐based disinfectants. These results support taurolidine as a potential adjunctive prophylactic agent to reduce device‐related infections during implantation procedures.

As implantable medical devices become indispensable to modern medicine, a silent threat grows alongside them: device‐associated infections. Despite decades of antibiotic innovation, infection rates keep climbing, costing lives and billions in healthcare expenses. This study explores taurolidine, a safe, broad‐spectrum antimicrobial, as a potential breakthrough for direct device surface disinfection, targeting the problem where it truly begins.XXXX

Figures